Self assembling diketopiperazine drug delivery system

• US 5,352,461 A
• Filed: 03/11/1992
• Issued: 10/04/1994
• Est. Priority Date: 03/11/1992
• Status: Expired due to Term

• Current Assignee: Mannkind Corporation
• Original Assignee: Pharmaceutical Discovery Corporation (Mannkind Corporation)
• Inventors: Glass, John, Feldstein, Robert, Steiner, Solomon S.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): BENSTON JR, WILLIAM E
• Application Number:
  US07/849,186
• Time in Patent Office: 937 Days
• Field of Search: 424/489, 424/490, 424/455, 424/493, 544/337, 544/231
• US Class Current: 424/493
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats

Abstract

Drug delivery systems have been developed based on the formation of diketopiperazine (or analogs) microparticles. In the preferred embodiment the microparticle is stable at low pH and disintegrates at physiological pH, and is particularly useful for oral drug delivery. In the most preferred embodiment the microparticles are formed in the presence of the drug to be delivered, for example, insulin or heparin. The diketopiperazine synthetic intermediates are preferably formed by cyclodimerization to form diketopiperazine derivatives at elevated conditions under dehydrating conditions, then precipitated with drug to be incorporated into microparticles.

Claims

1. A microparticulate system for drug delivery comprising:

diketopiperazine microparticles incorporating a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules,

wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.

2. The system of claim 1 wherein the diketopiperazine has the general structure ##STR3## wherein the ring atoms X at positions 1 and 4 are either O or N;

and at least one of the side-chain substituents R at positions 3 and 6 contains a carboxyl group.

3. The system of claim 2 wherein the structure is formed from amino acids selected from the group consisting of glutamic acid, aspartic acid, lysine, ornithine and diaminopropionic acid.

4. The system of claim 3 wherein the structure is selected from the group consisting of 2,5-diketo-3,6-di(aminobutyl)piperazine and 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine.

5. The system of claim 1 wherein the microparticles are stable at acidic pH and unstable at a more basic pH.

6. The system of claim 1 wherein the microparticles are unstable at acidic pH and stable at a more basic pH.

7. The system of claim 1 wherein the biological agent is insulin.

8. The system of claim 1 wherein the biological agent is heparin.

9. A method for making a microparticulate system for drug delivery comprising

forming diketopiperazines in a solution with a first defined pH at which the diketopiperazines are soluble,

adding to the diketopiperazine solution a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in a solution having a second defined pH precipitating the diketopiperazines to form microparticles of the diketopiperazines containing the biologically active agent.

10. The method of claim 9 wherein the diketopiperazine has the general structure ##STR4## wherein the ring atoms X at positions 1 and 4 are either O or N;

and at least one of the side-chain substituents R at positions 3 and 6 contains a carboxyl group.

11. The method of claim 9 wherein the structure is formed from amino acids selected from the group consisting of glutamic acid, aspartic acid, lysine, ornithine and diaminopropionic acid cyclized by blocking free β

-amino groups, heating in hot phenol under nitrogen at a temperature equivalent to 175°

C., and removing the blocking groups.

12. The method of claim 11 further comprising succinylating a side chain of the diketopiperazine having a free amino group.

13. The method of claim 9 wherein the structure is selected from the group consisting of 2,5-diketo-3,6-di(aminobutyl)piperazine and 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine.

14. A method for administering a biologically active agent to a patient comprising providing the agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in combination with microparticles formed of diketopiperazines, wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.

15. The method of claim 14 wherein the agent is selected from the group consisting of hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense, antigens, and antibodies.

16. The method of claim 14 wherein the microparticles are further encapsulated within an enteric coating.

17. The method of claim 14 wherein the microparticles are stable at acidic pH and unstable at neutral or basic pH.

18. The method of claim 14 wherein the microparticles are unstable at acidic pH and stable at neutral or basic pH.

19. The method of claim 14 wherein the biological agent is insulin.

20. The method of claim 14 wherein the biological agent is heparin.